(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr22.60 | 7.95% | 19.84% |
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.38% | 8.15% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
7.95% Forward Dividend Yield and 19.84% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.27.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 17.8. Meaning, the purchaser of the share is investing kr17.8 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.84%.
Sales Growth
VISTIN PHARMA’s sales growth is 10.6% for the current quarter and 6.6% for the next.
Moving Average
VISTIN PHARMA’s worth is below its 50-day moving average of kr22.94 and under its 200-day moving average of kr22.97.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VISTIN PHARMA’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
VISTIN PHARMA’s stock is valued at kr22.60 at 22:30 EST, below its 52-week high of kr25.10 and above its 52-week low of kr20.60.
More news about VISTIN PHARMA.
2. SARTORIUS STED BIO (DIM.PA)
0.38% Forward Dividend Yield and 8.15% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter is a negative 10.9% and positive 44.7% for the next.
Sales Growth
SARTORIUS STED BIO’s sales growth for the next quarter is 12.2%.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.2%, now sitting on 2.72B for the twelve trailing months.
Volatility
SARTORIUS STED BIO’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.51%, a negative 0.51%, and a positive 1.99%.
SARTORIUS STED BIO’s highest amplitude of average volatility was 1.44% (last week), 1.63% (last month), and 1.99% (last quarter).
More news about SARTORIUS STED BIO.
